Vaxer Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 0.55 M
as on 19-12-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 15.00 Cr
as on 19-12-2024
- Revenue 84.65%
(FY 2022)
- Profit 93.77%
(FY 2022)
- Ebitda 99.72%
(FY 2022)
- Net Worth 18.38%
(FY 2022)
- Total Assets 29.41%
(FY 2022)
About Vaxer Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 0.55 M.
The company currently has active open charges totaling ₹15.00 Cr.
Bodh Sikri, Aastha Dewan, Suman Malhotra, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999HR2011PLC122348
- Company No.
224400
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
30 Aug 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vaxer Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suman Malhotra  | Director | 27-Mar-2021 | Current |
| Bodh Sikri | Director | 16-Jan-2014 | Current |
| Aastha Dewan | Director | 27-Mar-2021 | Current |
| Anshul Sikri | Director | 30-Aug-2011 | Current |
| Pochiraju Rao | Director | 30-Aug-2011 | Current |
Financial Performance of Vaxer Pharma.
Vaxer Pharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 84.65% increase. The company also saw a substantial improvement in profitability, with a 93.77% increase in profit. The company's net worth Soared by an impressive increase of 18.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vaxer Pharma?
In 2022, Vaxer Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Abs Mercantiles Private LimitedActive 27 years 8 monthsBodh Sikri and Pochiraju Rao are mutual person
Aumento Pallinos Private LimitedActive 12 years 7 monthsBodh Sikri and Pochiraju Rao are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 28 Dec 2022 | ₹15.00 Cr | Open |
How Many Employees Work at Vaxer Pharma?
Vaxer Pharma has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vaxer Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vaxer Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
